Avid Bioservices Inc (CDMO)

[biopharm]

March 14, 2014 - ties to David Parkinson...

David Mott ex-Ambit Director re: Ambit Biosciences Raises Over $49 Million in Series D Financing

Elliott Sigal(ex-BMS), M.D., Ph.D., New Enterprise Associates

Now.. Ambit BOD at 9 total -- including Mark Foletta - ex-BMS

ok... ever since the posts above... and links with Peregrine and Ambit has clearly been identified as collaborators, we continue to keep an eye on their BOD's -- because its all who you know and those coming into the BOD at Ambit just may be part of the game... BMS ?

---------------------

Ambit Biosciences Announces Changes To Board Of Directors

June 4, 2014

Ambit Biosciences AMBI -0.15% , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the appointment of Jeffrey S. Hatfield to its Board of Directors and the resignation of board member Steven Elms.

Mr. Hatfield currently serves as the CEO and board member of Vitae Pharmaceuticals, a clinical-stage company building a portfolio of compounds for diseases with significant unmet medical need. Prior to joining Vitae Pharmaceuticals, Mr. Hatfield worked as a senior executive at Bristol-Myers Squibb in a variety of positions....20 years at BMS ( Sr. VP Virology / Immunology ..Responsible for $1 billion US Virology and Immunology Divisions, including: clinical development, marketing, medical affairs, sales, policy, pricing and public and community relations and now deals with partnerships/collaborations..etc..)

http://www.marketwatch.com/story/ambit-biosciences-announces-changes-to-board-of-directors-2014-06-04

http://www.linkedin.com/pub/jeff-hatfield/6/ab2/20

-----------------------------------------------------


Jeffrey S. Hatfield

Chief Executive Officer, Vitae Pharmaceuticals, Inc.

Prior to joining Vitae Pharmaceuticals, Mr. Hatfield spent nearly 20 years at Bristol-Myers Squibb in a variety of operating positions of increasing responsibility, including, most recently, as Senior Vice President of its Virology and Immunology Divisions, where he was responsible for all aspects of a $1 billion business. Other senior level positions held at Bristol included President and General Manager, Canada, and Vice President, U.S. Managed Health Care. Mr. Hatfield holds a bachelor's degree in Pharmacy from Purdue University and an M.B.A. from The Wharton School, University of Pennsylvania.

http://www.vitaepharma.com/view.cfm/39/Jeffrey-S-Hatfield

-------------------------------------------------

Bipartisan bill would help biotechs fund research

June 9, 2014

The political environment in Washington is difficult, but this minor tax reform, which leverages provisions already within the tax code, is supported by a bipartisan group of senators and would have a tremendous impact on how our industry funds research.

A simple change in timing - reducing the wait to recognize tax assets from 15 years to zero - could make a world of difference. This small modification would enable biotech companies to apply research incentives when and how they are meant to be used: to enable us to fund groundbreaking scientific advancement that has the potential to change and save lives around the world.

The U.S. economy is bolstered by the high-quality jobs created by our industry, and supporting R&D is key to maintaining America's lead in the innovation-centric 21st-century economy. As an industry, we should be mindful of the importance of early-stage financing and the promise that early-stage research holds. By supporting the Start-up Jobs and Innovation Act, we can help Congress make the right decision for innovators, patients, and the country as a whole.

http://www.philly.com/philly/opinion/inquirer/20140609_Bipartisan_bill_would_help_biotechs_fund_research.html